SCHEMBL5757342

SCHEMBL5757342

Cc1ccc(C(=O)NCc2cccc(Cl)c2)c(=O)n1-c1cccc(C#N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.50
KLKB1 P03952 2/20 0.46
KLK1 P06870 2/20 0.46
KDM4E B2RXH2 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
HCRTR1 O43613 1/20 0.45
NOTUM Q6P988 1/20 0.44
APEX1 P27695 1/20 0.44
PDE10A Q9Y233 1/20 0.44
EGLN2 Q96KS0 1/20 0.43
CCR1 P32246 1/20 0.42
METAP2 P50579 1/20 0.42
PTGER1 P34995 1/20 0.42
F2 P00734 1/20 0.42
PRSS1 P07477 1/20 0.42
PRSS2 P07478 1/20 0.42
PRSS3 P35030 1/20 0.42
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5761223 0.91 ELANE (0.55) ELANEKLKB1KLK1KMT2AMEN1
SCHEMBL5758113 0.91 ELANE (0.57) ELANEKMT2AMEN1HCRTR1APEX1
SCHEMBL5755743 0.91 RAB9A (0.49) ELANEKDM4ENPSR1KMT2AMEN1
SCHEMBL5756141 0.90 ELANE (0.52) ELANEKLKB1KLK1KDM4ENOTUM
SCHEMBL5757705 0.90 ELANE (0.55) ELANEKLKB1KLK1KDM4ENOTUM
SCHEMBL5758255 0.90 ELANE (0.51) ELANEKLKB1KLK1KMT2AMEN1
SCHEMBL5756946 0.89 ELANE (0.50) ELANEKLKB1KLK1KMT2ANOTUM
SCHEMBL5756777 0.88 ELANE (0.54) ELANEKLKB1KLK1NOTUMPDE10A
SCHEMBL5756911 0.87 ELANE (0.57) ELANEKLKB1KLK1KDM4EKMT2A
SCHEMBL5758181 0.87 ELANE (0.54) ELANEKDM4EKMT2AMEN1HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 ELANE 2/4885KLKB1 262/4885KLK1 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.